Causes of Hepatic Injury in Stevens-Johnson Syndrome
Hepatic injury in Stevens-Johnson syndrome (SJS) patients occurs primarily from three mechanisms: the same culprit drug causing both conditions, acute skin failure with multiorgan dysfunction, and secondary complications such as sepsis.
Primary Mechanisms of Liver Injury
1. Drug-Induced Liver Injury (DILI)
The most important cause is direct hepatotoxicity from the same medication triggering SJS/TEN 1. The UK guidelines explicitly identify liver dysfunction as a sequela of acute skin failure 1. Research confirms that DILI occurring concurrently with SJS is rare (4.8% of DILI cases) but carries significant mortality 2.
Key culprit drugs causing both SJS and hepatic injury include:
- Antiepileptic agents (carbamazepine, lamotrigine, phenytoin, phenobarbital) 1
- Sulfonamide antibiotics (sulfamethoxazole) 1
- Allopurinol 1
- Antiretroviral drugs (nevirapine) 1
- NSAIDs (oxicam NSAIDs, ibuprofen) 1, 3
Critical pitfall: The same drug causes both the skin reaction and liver injury simultaneously—this is not a separate process but a dual-organ manifestation of the same hypersensitivity reaction 2.
2. Acute Skin Failure and Multiorgan Dysfunction
Extensive epidermal detachment leads to systemic complications including liver dysfunction 1. The pathophysiology involves:
- Thermoregulatory dysfunction
- Large insensible fluid losses
- Haemodynamic instability
- Multiorgan failure cascade
The SCORTEN prognostic scoring system includes hepatic dysfunction as a mortality predictor, underscoring its significance in disease severity 1.
3. Secondary Complications
Systemic sepsis is the most frequent cause of death in SJS/TEN 1 and can precipitate hepatic injury through:
- Septic shock with hepatic hypoperfusion
- Direct bacterial/fungal hepatotoxicity
- Inflammatory cascade effects
Clinical Assessment Priorities
When evaluating hepatic injury in SJS patients, immediately assess for:
- Pre-existing hepatic dysfunction that may have altered drug metabolism and contributed to the reaction 1
- Timing of liver enzyme elevation relative to drug exposure (5-28 days is typical latency) 1
- Signs of acute liver failure: jaundice, coagulopathy, encephalopathy
- Concurrent sepsis indicators: fever, hypotension, reduced urine output, rising C-reactive protein 1
Prognostic Implications
The presence of jaundice dramatically worsens prognosis, with mortality rising to 45.5% when hepatic injury is severe enough to cause jaundice 2. Overall mortality in SJS with concurrent DILI is 36% 2.
Important exception: Children and HIV-infected patients have more favorable outcomes (11% and 12.5% mortality respectively) despite concurrent liver injury 2.
Management Implications
Discontinue all potential culprit drugs immediately 1, 4. This is the single most critical intervention, as continued exposure perpetuates both skin and hepatic injury.
Monitor hepatic function closely as part of multiorgan assessment in the ICU setting 1. The liver dysfunction may:
- Resolve with supportive care and drug withdrawal
- Progress to acute liver failure requiring transplantation (rare but reported) 5
- Complicate fluid resuscitation and medication dosing
Avoid hepatotoxic medications during treatment, including careful consideration of immunomodulatory agents and antibiotics that may further stress hepatic function.
Human leukocyte antigen (HLA) genotyping may identify genetic susceptibility to specific drug-induced reactions affecting both skin and liver 3, 6, 5, though this is primarily useful for future drug avoidance rather than acute management.